title: Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
abstract: OBJECTIVE
  In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12-24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong.
  
  
  METHODS
  We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program.
  
  
  RESULTS
  Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty-five (85%) patients received 12-week treatment and six patients received 24-week treatment; 26 (63%) patients received ribavirin combination. Thirty-nine (95%; 95% confidence interval 88.5-100%) patients had undetectable HCV RNA at 12-week post-treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation.
  
  
  CONCLUSIONS
  Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong.
authors.affiliation: Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
authors.forename: Henry Lik-Yuen
authors.initials: HL
authors.lastname: Chan
authors.affiliation: Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong.
authors.forename: Owen Tak-Yin
authors.initials: OT
authors.lastname: Tsang
authors.affiliation: Department of Medicine, Queen Elizabeth Hospital, Hong Kong.
authors.forename: Yee-Tak
authors.initials: YT
authors.lastname: Hui
authors.affiliation: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: James
authors.initials: J
authors.lastname: Fung
authors.affiliation: Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
authors.forename: Grace Chung-Yan
authors.initials: GC
authors.lastname: Lui
authors.affiliation: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: Ching-Lung
authors.initials: CL
authors.lastname: Lai
authors.affiliation: Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
authors.forename: Grace Lai-Hung
authors.initials: GL
authors.lastname: Wong
authors.affiliation: Department of Medicine, North District Hospital, Hong Kong.
authors.forename: Kam-Hon
authors.initials: KH
authors.lastname: Chan
authors.affiliation: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: David Yiu-Kuen
authors.initials: DY
authors.lastname: But
authors.affiliation: Department of Medicine, North District Hospital, Hong Kong.
authors.forename: Moon-Sing
authors.initials: MS
authors.lastname: Lai
authors.affiliation: Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong.
authors.forename: Wai-Cheung
authors.initials: WC
authors.lastname: Lao
authors.affiliation: Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
authors.forename: Carmen Ka-Man
authors.initials: CK
authors.lastname: Chan
authors.affiliation: Department of Medicine, Queen Elizabeth Hospital, Hong Kong.
authors.forename: Yip-Shun
authors.initials: YS
authors.lastname: Lam
authors.affiliation: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: Wai-Kay
authors.initials: WK
authors.lastname: Seto
authors.affiliation: Department of Medicine, Queen Elizabeth Hospital, Hong Kong.
authors.forename: Carlton
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: Man-Fung
authors.initials: MF
authors.lastname: Yuen
authors.affiliation: Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
authors.forename: Vincent Wai-Sun
authors.initials: VW
authors.lastname: Wong
mesh_terms: D015081:2-Naphthylamine; D000813:Anilides / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D002219:Carbamates / Q000008:administration & dosage*; D060085:Coinfection; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006723:Hong Kong; D047029:Lactams, Macrocyclic; D008103:Liver Cirrhosis; D016031:Liver Transplantation; D047028:Macrocyclic Compounds / Q000008:administration & dosage*; D011392:Proline / Q000031:analogs & derivatives; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage*; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014633:Valine
chemical_list: D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D013449:Sulfonamides; C586094:ombitasvir; D012254:Ribavirin; D014498:Uracil; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D014633:Valine; D019438:Ritonavir; C585405:paritaprevir
keywords: antiviral treatment; hepatitis C; real-life; ribavirin